Payment overview · 2025
General Payments
$826.12
42 reported records · 13 companies
Healthcare provider profile · identity verified
Fallon Houk, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CANTON, GA · NPI 1417628728
Verified facts
What the public records show
CMS Open Payments records show Fallon Houk, FNP received $826.12 in general payments during 2025 across 42 reported records.
ABBVIE INC. accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $358.66 | 43.4% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.61 | 17.6% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $74.99 | 9.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.63 | 4.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.90 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.80 | 3.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.61 | 3.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $25.08 | 3.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.84 | 3.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $20.72 | 2.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.48 | 2.5% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.18 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.62 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $826.12 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $358.66 | 20 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $78.75 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $74.99 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.86 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.63 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.61 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 89 |
| Losartan Potassium | Losartan Potassium | 232 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 186 | 66 |
| Lisinopril | Lisinopril | 183 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 50 |
| Trazodone Hcl | Trazodone Hcl | 136 | 48 |
| Metformin Hcl | Metformin Hcl | 133 | 48 |
| Omeprazole | Omeprazole | 133 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 48 |
| Montelukast Sodium | Montelukast Sodium | 121 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 29 |
| Metformin Hcl Er | Metformin Hcl | 106 | 37 |
| Carvedilol | Carvedilol | 103 | 42 |
| Gabapentin | Gabapentin | 100 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 27 |
| Bupropion Xl | Bupropion Hcl | 87 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 32 |
| Ezetimibe | Ezetimibe | 72 | 23 |
| Synthroid | Levothyroxine Sodium | 69 | 19 |
| Alprazolam | Alprazolam | 68 | 22 |
| Ozempic | Semaglutide | 67 | 20 |
| Buspirone Hcl | Buspirone Hcl | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 25 |
| Pregabalin | Pregabalin | 62 | 12 |
| Eliquis | Apixaban | 58 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 21 |
| Meloxicam | Meloxicam | 55 | 24 |
| Furosemide | Furosemide | 54 | 22 |
| Meclizine Hcl | Meclizine Hcl | 54 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 15 |
| Simvastatin | Simvastatin | 49 | 21 |
| Allopurinol | Allopurinol | 48 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 13 |
| Potassium Chloride | Potassium Chloride | 48 | 22 |
| Glimepiride | Glimepiride | 45 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 14 |
| Methocarbamol | Methocarbamol | 38 | 11 |
| Atenolol | Atenolol | 37 | 15 |
| Lorazepam | Lorazepam | 37 | 12 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | suppressed |
| Estradiol | Estradiol | 30 | 13 |
| Valsartan | Valsartan | 30 | 13 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 20 | 11 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $826.12 · 42 records | ABBVIE INC. | AIRSUPRA, AREXVY, BEXSERO, CONTRAVE, Cologuard Collection Kit, FARXIGA, GEMTESA, General - Pain Management, Heplisav-B, INTELLIS ADAPTIVESTIM, NEXPLANON, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error